SEROPOSITIVITY OF HEPATITIS B AND C AMONG SYRIAN MULTITRANSFUSED PATIENTS WITH HEMOGLOBINOPATHY

Background and objectives: Blood transfusion is a lifesaving therapy for patients with hemoglobinopathies. However, the need of frequent transfusion carries the risk of transmitting hepatitis B and C infections which are intermediately prevalent in Syria. Despite screening blood donations with sensi...

Full description

Saved in:
Bibliographic Details
Main Authors: Widad Yazaji, Wafa Habbal, Fawza Monem
Format: Article
Language:English
Published: PAGEPress Publications 2016-09-01
Series:Mediterranean Journal of Hematology and Infectious Diseases
Subjects:
Online Access:http://www.mjhid.org/index.php/mjhid/article/view/2604
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background and objectives: Blood transfusion is a lifesaving therapy for patients with hemoglobinopathies. However, the need of frequent transfusion carries the risk of transmitting hepatitis B and C infections which are intermediately prevalent in Syria. Despite screening blood donations with sensitive methods, the risk of transmission is still present when infectious blood is donated within the window period. This study aimed to investigate the incidence of HBV and HCV seropositivity, and its association with multiple transfusions among Syrian hemoglobinopathies patients. Materials and Methods: HBsAg, anti-HBc, anti-HBs and anti-HCV were tested for 159 Syrian multitransfused patients by Enzyme Linked Immunosorbant Assay (ELISA). Results: Thirty-nine of 159 (24.5%) multitransfused patients were HBsAg/anti-HBc or anti-HCV positive, 26 (16%) of which never visited the dentist, and they either tested postsurgically negative for HBsAg and anti-HCV or never underwent a surgical procedure. On the contrary of anti-HCV seropositivity, HBsAg/anti-HBc seropositivity was significantly associated with the number of blood transfusions, number of blood units and age (P < 0.001). Conclusion: About one-sixth of our patients most likely acquired HBV/HCV infection via blood transfusion. Administering HBV vaccine, ensuring the immune status, and monitoring hepatitis markers might considerably minimize the incidence of viral hepatitis among multitransfused patients.
ISSN:2035-3006